Induction of Smad1 by MT1-MMP contributes to tumor growth

International Journal of Cancer

Volumn 121, Issue 5, 2007, Pages 966-977

  Freudenberg, Jaclyn A ^a   Chen, Wen Tien ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

MT1 MMP; RNA interference; Smad1; TGF ; Tumor growth

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE 14; SMAD1 PROTEIN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INDUCTION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; MATRIX METALLOPROTEINASE 14; MICE; MICE, NUDE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 34547115457     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22754     Document Type: Article

References (44)

1. Nonaka T, Nishibashi K, Itoh Y, Yana I, Seiki M. Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/ matrix metalloproteinase-14 in vivo. Mol Cancer Ther 2005;4:1157-66.
2. Sounni NE, Baramova EN, Munaut C, Maquoi E, Frankenne F, Foidart JM, Noel A. Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. Int J Cancer 2002;98:23-8.
3. Soulie P, Carrozzino F, Pepper MS, Strongin AY, Poupon MF, Montesano R. Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene 2005;24:1689-97.
4. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
5. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993;53:4391-8.
6. Popik W, Inglot AD. Interactions of interferons and transforming growth factors during clonal growth of mouse or human cells in soft agar and in mice. Int J Cancer 1987;40:108-13.
7. Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA. Consequences of altered TGF-β expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene 2002;21:108-18.
8. Langenfeld EM, Calvano SE, bou-Nukta F, Lowry SF, Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 2003;24:1445-54.
9. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, Buerger H. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 2005;206:366-76.
10. Liu X, Yue J, Frey RS, Zhu Q, Mulder KM. Transforming growth factor β signaling through Smad1 in human breast cancer cells. Cancer Res 1998;58:4752-7.
11. Munoz O, Fend F, de BR, Husson H, Astier A, Freedman AS. TGFβ-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia 2004;18:2015-25.
12. Pouliot F, Blais A, Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003;63:277-81.
13. Korchynskyi O, Landstrom M, Stoika R, Funa K, Heldin CH, Ten DP, Souchelnytskyi S. Expression of Smad proteins in human colorectal cancer. Int J Cancer 1999;82:197-202.
14. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 2006;25:685-92.
15. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature 1997;389:618-22.
16. Yue J, Frey RS, Mulder KM. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFβ. Oncogene 1999;18:2033-7.
17. Abe H, Matsubara T, Iehara N, Nagai K, Takahashi T, Arai H, Kita T, Doi T. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004;279:14201-6.
18. Hu MC, Rosenblum ND. Smad1, {β}-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription. Development 2005;132:215-25.
19. Pouliot F, Labrie C. Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 2002;172:187-98.
20. Ng KW, Leong DT, Hutmacher DW. The challenge to measure cell proliferation in two and three dimensions. Tissue Eng 2005;11:182-91.
21. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58.
22. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003;34:263-4.
23. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 2002;100:2-8.
24. Rutka JT, Giblin JR, Apodaca G, DeArmond SJ, Stern R, Rosenblum ML. Inhibition of growth and induction of differentiation in a malignant human glioma cell line by normal leptomeningeal extracellular matrix proteins. Cancer Res 1987;47:3515-22.
25. Meck RA, Ingram M, Meck JM, McCullough JL, Wu MC, Yunis AA. Establishment and cell cycle kinetics of a human squamous cell carcinoma in nude mice and in vitro. Cancer Res 1981;41:1076-85.
26. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST, Low MJ, Holsboer F, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003;100:1034-9.
27. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht LT, McCarthy JB. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 2004;122:167-76.
28. Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, Kawase I, Hayashi S, Sone S. CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res 2005;15:365-72.
29. Gullick WJ. The c-erbB3/HER3 receptor in human cancer. Cancer Surv 1996;27:339-49.
30. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004;6:R478-87.
31. Lunter PC, van Kilsdonk JW, van BH, Cornelissen IM, Bergers M, Willems PH, van Muijen GN, Swart GW. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 2005;65:8801-8.
32. Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 2006;59:403-9.
33. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology 2004;45:103-18.
34. Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaisse JM, Foged NT. Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 2002;277:44061-7.
35. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL. The integrin {α}v{β}8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-{B}1. J Cell Biol 2002;157:493-507.
36. Yue J, Hartsough MT, Frey RS, Frielle T, Mulder KM. Cloning and expression of a rat Smad1: regulation by TGFβ and modulation by the Ras/MEK pathway. J Cell Physiol 1999;178:387-96.
37. Candia AF, Watabe T, Hawley SH, Onichtchouk D, Zhang Y, Derynck R, Niehrs C, Cho KW. Cellular interpretation of multiple TGF-β signals: intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development 1997;124:4467-80.
38. Leivonen SK, Ala-aho R, Koli K, Grenman R, Peltonen J, Kahari VM. Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene 2006;25:2588-600.
39. Pardali K, Kowanetz M, Heldin CH, Moustakas A. Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J Cell Physiol 2005;204:260-72.
40. Okada A, Tomasetto C, Lutz Y, Bellocq JP, Rio MC, Basset P. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997;137:67-77.
41. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
42. Vihinen P, la-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203-20.
43. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005;5:285-98.
44. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003;252:305-29.